. Author manuscript; available in PMC: 2024 Feb 1.

Published in final edited form as: Lancet Rheumatol. 2023 Jan 24;5(2):e67–e76. doi: 10.1016/s2665-9913(23)00003-6

Table 3.

Summary of treatment-emergent adverse events (safety analysis population)

	Zilucoplan 0·3mg/kg N=12 n (%)^*	Placebo N=15 n (%)^*
Any TEAE	9 (75·0)	13 (86·7)
Most Frequent TEAE^†
Headache	4 (33·3)	4 (26·7)
Nausea	3 (25·0)	3 (20·0)
Serious TEAE	0	3 (20·0)
TEAE Resulting in Permanent Withdrawal from Study Medication	0	0
Treatment-related TEAE	4 (33·3)	5 (33·3)
Headache	2 (16·7)	2 (13·3)
Nausea	2 (16·7)	1 (6·7)
Vertigo	0	2 (13·3)
Treatment Related Serious TEAE	0	0
Deaths (TEAEs leading to death)	0	0

TEAE=treatment-emergent adverse event.

n=number of participants reporting at least one TEAE in that category

^†

TEAEs reported in >2 participants in either treatment group.